Market Overview

Seattle Genetics Highlights ADCETRIS Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate Collaborator Data at ASCO


Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted ongoing clinical
development programs for ADCETRIS (brentuximab vedotin) in frontline
Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress
with collaborator antibody-drug conjugate (ADC) programs that were
presented at the 49th Annual Meeting of the American Society
of Clinical Oncology being held May 31 – June 4, 2013, in Chicago, IL.
The phase 3 clinical trials, called ECHELON-1 and ECHELON-2, are
evaluating ADCETRIS for the frontline treatment of HL and MTCL,
including patients with systemic anaplastic large cell lymphoma (sALCL)
and other types of peripheral T-cell lymphoma. ADCETRIS is an ADC
directed to CD30, a defining marker of HL and sALCL, which was granted
accelerated approval by the FDA in August 2011 for relapsed HL

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (SGEN)

View Comments and Join the Discussion!